Adaptimmune Therapeutics Current Ratio 2015-2021 | ADAP

Adaptimmune Therapeutics current ratio from 2015 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Adaptimmune Therapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.34B $0.04B 8.15
2021-03-31 $0.36B $0.03B 11.48
2020-12-31 $0.40B $0.04B 10.19
2020-09-30 $0.43B $0.04B 12.23
2020-06-30 $0.46B $0.04B 11.88
2020-03-31 $0.23B $0.03B 7.64
2019-12-31 $0.12B $0.03B 3.51
2019-09-30 $0.15B $0.04B 3.93
2019-06-30 $0.18B $0.03B 6.19
2019-03-31 $0.20B $0.02B 8.55
2018-12-31 $0.23B $0.02B 9.46
2018-09-30 $0.26B $0.03B 8.85
2018-06-30 $0.16B $0.04B 3.82
2018-03-31 $0.20B $0.05B 3.77
2017-12-31 $0.23B $0.07B 3.10
2017-09-30 $0.25B $0.07B 3.70
2017-06-30 $0.24B $0.03B 7.86
2017-03-31 $0.22B $0.03B 6.99
2016-12-31 $0.20B $0.04B 4.94
2016-09-30 $0.20B $0.02B 8.81
2016-06-30 $0.22B $0.02B 10.84
2016-03-31 $0.24B $0.02B 12.03
2015-12-31 $0.27B $0.03B 9.57
2015-09-30 $0.29B $0.03B 8.52
2015-06-30 $0.30B $0.03B 11.03
2015-03-31 $0.00B 0.00
2014-12-31 $0.14B $0.05B 2.94
2014-06-30 $0.05B $0.05B 1.02
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.813B $0.004B
Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76